Investigating how psychedelics such as psilocybin act on serotonin receptors, researchers shed new light on how the drugs affect consciousness and assist in treating a range of mental health disorders.
Prescribing psychedelic therapies including MDMA and psilocybin in combination with counseling and psychotherapy improve symptoms for those with PTSD.
A new study reports two doses of the psychedelic compound psilocybin reduced heavy alcohol consumption by 83% when combined with therapy for those with alcohol use disorder.
Study reveals those who microdosed psilocybin for 30 days showed greater improvements in mood, mental health, and psychomotor abilities than those who did not microdose. The findings have positive implications for the use of psychedelics to help treat mental health disorders.
A new study will explore how psilocybin affects different networks and serotonin function in the brains of autistic adults.
Researchers explore the effect psychedelics have on the brain and how they are effective at treating depression.
People with depression who responded to psilocybin therapy showed an increase in brain connectivity for up to three weeks following treatment. The increased brain connectivity was correlated with self-reported improvements in depression symptoms.
Opioid use disorder is 30% less common in those who used psilocybin compared to those who have never been exposed to the psychedelic. Researchers say psilocybin may protect against opioid addiction by affecting the transmission of dopamine and serotonin.
The antidepressant effect of psilocybin-assisted therapy, in combination with psychotherapy, appears to provide up to a year of symptom relief for some patients with major depressive disorder.
Study demonstrates the safety and feasibility of psilocybin for the treatment of mental health disorders.